New hope for macular disease: personalized eye injections show promise
NCT ID NCT05666804
First seen Jan 11, 2026 · Last updated May 25, 2026 · Updated 13 times
Summary
This study tested a personalized treatment plan using the drug brolucizumab for people with a specific eye condition called polypoidal choroidal vasculopathy (PCV), which causes vision problems. 148 adults who had not received prior treatment for PCV took part. The goal was to see if a tailored injection schedule could improve vision and control the disease over 60 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MACULAR POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Novartis Investigative Site
Daegu, Dalseo Gu, 42602, South Korea
-
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, 13620, South Korea
-
Novartis Investigative Site
Daejeon, Korea, 35015, South Korea
-
Novartis Investigative Site
Seoul, Korea, 02447, South Korea
-
Novartis Investigative Site
Seoul, Korea, 03080, South Korea
-
Novartis Investigative Site
Busan, 48108, South Korea
-
Novartis Investigative Site
Busan, 49241, South Korea
-
Novartis Investigative Site
Busan, 613-815, South Korea
-
Novartis Investigative Site
Daegu, 705703, South Korea
-
Novartis Investigative Site
Gwangju, 61469, South Korea
-
Novartis Investigative Site
Seoul, 01000, South Korea
-
Novartis Investigative Site
Seoul, 01869, South Korea
-
Novartis Investigative Site
Seoul, 03722, South Korea
-
Novartis Investigative Site
Seoul, 05505, South Korea
-
Novartis Investigative Site
Seoul, 06273, South Korea
Conditions
Explore the condition pages connected to this study.